The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMycelx Di Regulatory News (MYX)

Share Price Information for Mycelx Di (MYX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 54.50
Bid: 53.00
Ask: 56.00
Change: 0.00 (0.00%)
Spread: 3.00 (5.66%)
Open: 54.50
High: 54.50
Low: 54.50
Prev. Close: 54.50
MYX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

New Project Awards and Operations Update

30 Aug 2022 07:00

RNS Number : 4589X
MyCelx Technologies Corporation
30 August 2022
 

30 August 2022

 

MYCELX Technologies Corporation

 

New Project Awards and Operations Update

 

MYCELX Technologies Corporation ("MYCELX" or the "Company"), the clean water and clean air technology company, is pleased to provide an update on recent operational momentum, including the award of new contracts in the Middle East.

 

MYCELX has secured a new purchase order from SABIC Agri-Nutrients, a SABIC affiliate, to provide clean water for optimal performance in their fertiliser production process. This installation is the fourth project with this customer and demonstrates MYCELX's status as vendor of choice for the toughest water treatment. The Company has also expanded its footprint in Saudi Arabia with the award of a short-term emergency response project with a leading independent petrochemical company. The Company expects that this initial project will develop into a longer-term partnership thereby helping to meet its goal of client diversification. In addition to this exciting work, MYCELX announces the renewal of two water treatment contracts with long-standing customers in the region and the establishment of a Master Framework Agreement with SABIC for Wastewater Treatment. This is a testament to the quality of the work and benefits MYCELX brings, the relationship the Company has with its customers and the excellence of its technology. These projects underpin the 2022 revenue forecast and the Company remains on track to meet current guidance.

 

MYCELX confirms the successful, ongoing trial of its unique REGEN product for use in Enhanced Oil Recovery with a major producer in the Middle East. The Company is also in advanced negotiations with another major producer for a REGEN retrofit of their existing equipment to benefit from MYCELX's superior removal efficiency, cost savings and the potential to increase flow rate by up to 30%. Beyond the Middle East, the Company is pleased to announce that a further REGEN system has now been installed and commissioned in Nigeria.

 

As part of MYCELX's strategy to expedite its access to the significant PFAS remediation market, the Company is pleased to confirm that it is currently in discussions with several global water treatment companies, an environmental engineering firm and companies focused on treatment for the residential market. Through these channels, the Company expects to run further PFAS trials in the USA. These will build upon the successful recent trial, through the Company's Australian distribution partner, at a landfill leachate installation where MYCELX PFAS technology was proven to remove contaminants down to non-detectable levels cost effectively. This broader capability in PFAS removal places MYCELX in a strong position as a cost-effective solution, as the enormity of the PFAS global problem is exposed and the need for complete removal gains public attention. We look forward to updating shareholders with further developments in the coming months.

 

Connie Mixon, CEO of MYCELX, said:

 

"I am pleased to provide an update in the Middle East, where our team continues to secure our position as the 'supplier of choice' for clean water solutions. In particular, REGEN is proving its performance and sustainability credentials through the successful ongoing trial in the sizeable enhanced oil recovery market. We look forward to providing more updates, including with regards to our critical PFAS remediation solution."

 

 

For further information please contact:

 

MYCELX Technologies Corporation

Connie Mixon, CEO

Kim Slayton, CFO

 

 

 

Tel: +1 888 306 6843

Canaccord Genuity, Nominated Adviser

Henry Fitzgerald-O'Connor

Gordon Hamilton

 

 

Tel: + 44 20 7523 8000

Celicourt

Mark Antelme

Jimmy Lea

 

Tel: +44 20 8434 2754

 

The relevant notifications set out below are provided in accordance with the requirements of Article 19 of the EU Market Abuse Regulation (No. 596/2014).

 

Notes to Editors

 

Through its revolutionary water technology, MYCELX brings its customers material benefits in terms of performance enhancement, cost savings and significantly improved environmental footprints. MYCELX supports leading international customers in the Oil & Gas industry, as well as the PFAS remediation market. MYCELX also provides advanced air filtration technology for manufacturing and industrial facilities, effectively removing oil particles and biologicals to maintain continuous and safe air quality levels.

 

For more information, visit www.MYCELX.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
STREANPNASFAEEA
Date   Source Headline
4th Mar 20167:00 amRNSTrading Update
11th Jan 20165:30 pmRNSHolding(s) in Company
29th Dec 20152:23 pmRNSHolding(s) in Company
18th Dec 201510:13 amRNSHolding(s) in Company
15th Dec 20155:25 pmRNSHolding(s) in Company
15th Dec 20155:24 pmRNSHolding(s) in Company
11th Dec 20157:00 amRNSTrading Update
3rd Dec 201511:33 amRNSBlocklisting Interim Review
1st Oct 20157:00 amRNSProgress Update on Trials
10th Sep 20157:00 amRNSHalf Yearly Report
28th Aug 20157:00 amRNSRestricted Common Shares to be Traded in CREST
20th Aug 20157:00 amRNSDirector Resignation
17th Aug 20157:00 amRNSProgress Report on Trials and Cost Reduction
29th Jul 20152:01 pmRNSHolding(s) in Company
22nd Jul 20157:00 amRNSTrading Statement
1st Jul 20157:00 amRNSChange of Adviser
5th Jun 20157:00 amRNSDirector/PDMR Shareholding
28th May 20159:48 amRNSBlocklisting Interim Review
21st May 20153:01 pmRNSDirector/PDMR Shareholding
19th May 20154:01 pmRNSResult of Annual Meeting
19th May 20157:00 amRNSAnnual Meeting Statement
17th Apr 20157:00 amRNSMailing of 2014 Annual Report & Notice of AGM
20th Mar 20157:00 amRNS2014 Preliminary Results
15th Jan 20155:39 pmRNSTrading Update
5th Jan 20157:00 amRNSClose of US Placing
2nd Jan 201512:00 pmRNSHolding(s) in Company
22nd Dec 201412:54 pmRNSHolding(s) in Company
10th Dec 20147:00 amRNSEquity Placing
2nd Dec 20147:00 amRNSEquity Placing
27th Nov 20143:58 pmRNSBlocklisting Interim Review
19th Nov 20147:00 amRNSTrading Statement
12th Sep 20147:00 amRNSHalf Year Results Statement
26th Aug 20147:00 amRNSMiddle East Contract Win
7th Jul 20147:00 amRNSHalf Year Trading Update & Contract Wins
13th May 20143:31 pmRNSResult of Annual Meeting
29th Apr 20144:44 pmRNSBlocklisting Interim Review
22nd Apr 201410:02 amRNSAnnual Report & Accounts Posted
20th Mar 20147:00 amRNS2013 Preliminary Results
30th Jan 20147:00 amRNSYear End Trading Update & Contract Wins
10th Dec 20133:29 pmRNSTotal Voting Rights
4th Dec 20133:24 pmRNSHolding(s) in Company
26th Nov 20137:00 amRNSFast-to-market lease programme yields new leasings
30th Oct 20133:21 pmRNSDirector/PDMR Shareholding
29th Oct 20131:56 pmRNSBlocklisting Interim Review
16th Oct 20133:12 pmRNSDirector Shareholding / Warrant Exercise
3rd Oct 20137:00 amRNSInvestor Presentation
12th Sep 20137:00 amRNSHalf Year Results Statement
19th Aug 20139:06 amRNSNotice of Results
7th Aug 20139:29 amRNSBalance of respective lines of stock
10th Jun 20135:16 pmRNSChange of Main Office Address

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.